India-US Trade Deal Enters Final Stretch — 6 Stocks Already Feeling the Impact

India-US Trade Deal Enters Final Stretch — 6 Stocks Already Feeling the Impact

Today, September 1, India's Commerce Ministry sits down with exporters, industry bodies FICCI, CII, and Assocham to prepare for Commerce Minister Piyush Goyal's upcoming talks with US Trade Representative Jamieson Greer. A bilateral trade deal — which could slash US tariffs on Indian goods from as high as 50% to roughly 18% — would be the single biggest catalyst for India's export-heavy companies in years.

But you don't need to guess who benefits. Company filings already tell the story. Here are six stocks across four sectors whose managements have explicitly discussed the trade deal's impact on their businesses.

Specialty Chemicals: Aarti Industries (AARTIIND)

Aarti Industries, India's largest manufacturer of benzene-based chemicals, is perhaps the clearest beneficiary. In their Q3 FY26 earnings call, management stated that "the recently announced US-India trade deal provides a sigh of relief and is expected to boost the business in the US in coming times." The company specifically noted that its PDA (para-dichlorobenzene) capacity utilization was "impacted on account of US tariffs" with "improvement linked to US-India trade deal."

The numbers back up the optimism. In Q4 FY26, Aarti reported revenue of Rs 2,422 crore (up 9% year-on-year) and EBITDA of Rs 342 crore (up 29% YoY). Profit after tax jumped 43% to Rs 137 crore. Management has guided for EBITDA margins of 14-15%, with US volumes for MMA and PDCB already resuming — even while partially absorbing tariff costs.

Apparel: Pearl Global Industries (PGIL) and Gokaldas Exports (GOKEX)

India's apparel exporters have taken the hardest hit from tariffs. Pearl Global Industries, which manufactures across India, Bangladesh, Vietnam, and Guatemala, disclosed in its Q2 FY26 results that it achieved revenue of Rs 1,313 crore while absorbing a "50% US tariff on India." The company posted adjusted EBITDA margins of 9.3%, improving by 108 basis points year-on-year despite the tariff headwind. Management noted that "USA, our biggest market, has now an MFN plus Section 301 tariff on our apparel" — a burden that a trade deal would directly relieve.

Gokaldas Exports paints a similar picture but with a sharper growth angle. The company's consolidated EBITDA grew 48%, and its export growth of 33% outpaced India's overall export growth of 13.5%. Per their recent quarterly results, management noted that "any positive outcome on US-India trade deal would offset" the reciprocal tariff impact. The company is also exploring fabric capacity expansion that could generate Rs 1,800 crore in revenue at full capacity — investment that a favorable trade deal would accelerate.

Medical Devices: Poly Medicure (POLYMED)

An often-overlooked beneficiary sits in the medtech sector. Poly Medicure's investor presentation includes a dedicated section titled "US India Trade Deal Impact on Medtech Sector," noting that the "US duty cut from 50% to ~18% makes Indian medtech — especially disposables — significantly more cost-competitive than Chinese imports." The company identified three tailwinds: price competitiveness in the US market, export expansion potential, and China+1 sourcing advantages. Poly Medicure's subsidiary Citieffe already has 35-40% of its business in the US and Mexico, positioning it as a direct beneficiary.

Steel Pipes: Surya Roshni (SURYAROSNI)

Surya Roshni provides one of the most concrete examples of tariff relief already translating to results. In their most recent quarterly earnings call, management stated that "the impact of the tariff war will be positive on India" and that growth was "led by section pipes, ERW API pipes — supported by a sharp rise in export volumes following the opening of our US market." The results were striking: EBITDA rose 63% year-on-year to Rs 84 crore, with EBITDA per ton improving to Rs 4,006 from Rs 2,922. Exports now account for roughly 17% of the steel division's revenue.

Packaging Machinery: Mamata Machinery (MAMATA)

On the cautionary side, Mamata Machinery shows what tariff uncertainty can do to a smaller exporter. The US is a large export market for the company, particularly for its converting machinery business. Revenue fell from Rs 111 crore in Q4 FY25 to Rs 73.9 crore in Q4 FY26, and full-year EBITDA compressed from Rs 54.64 crore (21.4% margin) to Rs 19.1 crore (8.2%). However, management called these headwinds "transient" and reaffirmed its commitment to the US market, suggesting a deal could trigger a sharp recovery.

What Retail Investors Should Do

The India-US trade deal is not yet finalized, and today's Commerce Ministry meeting is a preparatory step. But company filings reveal two clear camps: businesses already adapting (Aarti Industries, Surya Roshni, Gokaldas) and those waiting for tariff clarity to unlock pent-up demand (Pearl Global, Poly Medicure, Mamata Machinery). Investors should watch for three signals — the Goyal-Greer meeting outcome, specific tariff rates by sector, and any reciprocal tariff changes from August onward. Companies with diversified manufacturing bases across multiple geographies (like Pearl Global) carry less binary risk than pure India-to-US exporters. Position sizing should reflect that a deal may still take weeks to formalize, but the directional momentum is clearly positive.

Data sourced from company filings on NSE via Xaro.